CSTL vs. GTH, XGN, FTRE, VCYT, CDNA, VRDN, FLGT, CELC, SERA, and BDSX
Should you be buying Castle Biosciences stock or one of its competitors? The main competitors of Castle Biosciences include Genetron (GTH), Exagen (XGN), Fortrea (FTRE), Veracyte (VCYT), CareDx (CDNA), Viridian Therapeutics (VRDN), Fulgent Genetics (FLGT), Celcuity (CELC), Sera Prognostics (SERA), and Biodesix (BDSX). These companies are all part of the "medical" sector.
Genetron (NASDAQ:GTH) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.
10.7% of Genetron shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 7.2% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Castle Biosciences has higher revenue and earnings than Genetron.
Castle Biosciences has a consensus target price of $31.57, suggesting a potential upside of 35.73%. Given Genetron's higher possible upside, analysts clearly believe Castle Biosciences is more favorable than Genetron.
Genetron has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.
In the previous week, Castle Biosciences had 4 more articles in the media than Genetron. MarketBeat recorded 4 mentions for Castle Biosciences and 0 mentions for Genetron. Genetron's average media sentiment score of 0.95 beat Castle Biosciences' score of 0.00 indicating that Castle Biosciences is being referred to more favorably in the news media.
Genetron has a net margin of 0.00% compared to Genetron's net margin of -12.28%. Castle Biosciences' return on equity of 0.00% beat Genetron's return on equity.
Castle Biosciences received 79 more outperform votes than Genetron when rated by MarketBeat users. Likewise, 62.31% of users gave Castle Biosciences an outperform vote while only 33.33% of users gave Genetron an outperform vote.
Summary
Castle Biosciences beats Genetron on 12 of the 15 factors compared between the two stocks.
Get Castle Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Castle Biosciences Competitors List
Related Companies and Tools
